Prof Sarah Wordsworth, Population Health and Health Economics (WP6)
Prof Sarah Wordsworth joined the Health Economics Research Centre (HERC) in January 2003 and developed a research programme on the economics of genetic and genomic technologies. Of particular interest is the economics of translating high-throughput sequencing technologies such as whole-genome sequencing in rare diseases and cancer into health care systems.
Her other research interests include antimicrobial resistance (AMR) where she explores the contribution that health economics can bring to this important health area and identify barriers to implementing interventions for reducing AMR. She also addresses methodological challenges in trial-based economic evaluations in the areas of surgery for obesity, lung cancer surgery, cardiovascular disease and eye disease.
Sarah undertakes policy work and leads the Health Economics Genomics England Clinical Interpretation Partnership (GeCIP). for the UK’s 100,000 Genomes Project. This is the largest sequencing initiative in the world and sequenced 100,000 entire genomes from around 70,000 National Health Service patients with rare diseases and cancer.
As a Senior Fellow at St. Anne’s College, Prof Sarah Wordsworth is a member of the college Governing Body, graduate advisor for DPhil and MSc students and part of the Centre for Personalised Medicine (St. Anne’s and Wellcome Trust Centre for Human Genetics).
Sarah teaches a variety of undergraduate and graduate students. She is Co-Director of the MSc in Precision Cancer Medicine (University of Oxford) and supervises DPhil students.
She worked in the Health Economics Research Unit at the University of Aberdeen from 1995-2002, after completing my MSc in Health Economics in 1995 at the University of York.
Prof Sarah Wordsworth is leading the health economics stream of Work Package 6 Primary Care / Population Health and Health Economics.